Welcome to our dedicated page for Ideaya Biosciences news (Ticker: IDYA), a resource for investors and traders seeking the latest updates and insights on Ideaya Biosciences stock.
IDEAYA Biosciences, Inc. develops precision medicine oncology therapies for molecularly defined cancer populations. The company’s news centers on targeted small-molecule programs, synthetic lethality research, antibody-drug conjugates and biomarker-guided clinical development across solid tumors.
Recurring updates include darovasertib clinical data in uveal melanoma, including combination work with crizotinib, as well as pipeline developments for programs such as IDE849, IDE161, IDE574 and IDE397. Company announcements also cover medical-meeting presentations, FDA regulatory interactions, clinical collaboration activity, quarterly financial results, cash runway commentary and equity compensation grants under Nasdaq inducement rules.
IDYA has partnered with GlaxoSmithKline (GSK) to advance Synthetic Lethality programs, including MAT2A and Pol Theta. These programs, projected to enter clinical trials in the next three years, utilize innovative approaches to target cancer-specific vulnerabilities. IDEAYA will manage the MAT2A program's early development, covering initial costs, while sharing profits with GSK. The collaboration aims to enhance precision medicine in oncology, focusing on significant solid tumors. Regulatory clearance is required to finalize the partnership.